About the Journal
Commissioning Editor: Claire Attwood
Production Manager: Jonathan Collard
2012 ISI Impact Factor: 2.483
ISSN: 1472-8214 (print), 1744-7623 (electronic)
An update on emerging drugs for Hodgkin Lymphoma
Bastian von Tresckow,
Emerging drugs for the treatment of gastroparesis
William L Hasler
Emerging drugs for allergic conjunctivitis
Giorgio Walter Canonica
Emerging drugs for the treatment of tobacco dependence: 2022 update
Muhamad Y Elrashidi,
Jon O Ebbert
Emerging drugs for T-cell lymphoma
Henry Miles Prince
Expert Opinion and Expert Reviews are now on facebook!
December 18, 2013The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
Editorial highlight ? New emerging drugs for the treatment of urothelial carcinoma
November 29, 2013The highlight of the month for the December issue is the review: Emerging drugs for urothelial carcinoma, by Sonpavde and Gartrell. Read more here..
This week in Expert Opinion
November 8, 2013This week in Expert Opinion, we look at the emerging treatments for some of the world?s most prevalent diseases covering: autoimmune, infectious and cardiovascular disease. Click above to find out more.
Editor?s pick for September 2013
August 27, 2013This month, the Editor has picked the timely written piece, ?Emerging antithrombotic drugs for acute coronary syndrome?, as the editorial highlight of the month, focusing on three novel antithrombotic agents in particular.
Editor?s pick for June 2013
June 7, 2013This month the editor?s pick is the review by Rinne et al: ?Update on bevacizumab and other angiogenesis inhibitors for brain cancer?, which thoroughly describes an important emerging area of neuro-oncology treatment.
Editor?s pick March 2013 (EOMD)
March 15, 2013Emerging drugs for axial spondyloarthritis including ankylosing spondylitis
(Noemi Busquets-Perez, Helena Marzo-Ortega and Paul Emery)
Our March editor?s pick is a review on current phase II and III drugs for the treatment of axial spondyloarthritis. While current treatment includes NSAIDs and TNFi, new biomarkers have generated the development of new drugs. Read more.
Editor?s pick December 2012 (EOMD)
November 26, 2012Emerging human papillomavirus vaccines
(Barbara Ma, Bharat Maraj, Nam Phuong Tran, Jayne Knoff, Alexander Chen, Ronald D Alvarez, Chien-Fu Hung & T.-C. Wu)
Our December issue includes an authoritative and comprehensive review on current research into prophylactic and therapeutic HPV vaccines. Read more.
Editor?s pick September 2012 (EOMD)
August 29, 2012Emerging treatment for chronic migraine and refractory chronic migraine
(Luana Lionetto, Andrea Negro, Stefano Palmisani, Giovanna Gentile, Maria Rosaria Del Fiore, Marco Mercieri, Maurizio Simmaco, Thomas Smith, Adnan Al-Kaisy, Roberto Arcioni, Paolo Martelletti)
In the September issue of Expert Opinion on Emerging Drugs, Lionetto and colleagues review new drugs for the treatment of the debilitating disorder of chronic migraine as well as chronic migraine that is resistant to prophylactic treatment. Read more.
Editor’s Pick April 2012 (EOMD)
March 28, 2012
Emerging drugs for major depressive disorder (KR Connolly, ME Thase)
There are unmet needs for the effective and acceptable treatment of major depressive disorder. In this paper, the authors review current first-line antidepressants and discuss the background, clinical trial data and significance of recently introduced antidepressants and approved augmentation agents. A thorough discussion ofÿall medications currently in Phase II or later clinical trials, follows. Thisÿincludes a brief review of the pharmacology and physiology of the related system which each drug targets. Read more.
Let’s be clear – Expert Opinion on ethical publishing
March 27, 2012In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.